IFNA1 and hepatitis C virus infection: Sofosbuvir plus RBV and ombitasvir-paritaprevir-ritonavir plus RBV were the IFN-free regimens available for the treatment of patients infected with HCV GT2, while sofosbuvir plus RBV was recommended for the treatment of HCV GT3 to GT6 in Japan according to Japan Society of Hepatology (JSH) 2016 guidelines for the management of hepatitis C virus infection (10, 12, 13).